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Abstract
In this study, we attempt to target the mitogen-activated protein kinase (MAPK) pathway in acute myeloid leukemia
(AML) cells using a recombinant anthrax lethal toxin (LeTx). LeTx consists of protective antigen (PrAg) and lethal
factor (LF). PrAg binds cells, is cleaved by furin, oligomerizes, binds three to four molecules of LF, and undergoes
endocytosis, releasing LF into the cytosol. LF cleaves MAPK kinases, inhibiting the MAPK pathway. We tested
potency of LeTx on a panel of 11 human AML cell lines. Seven cell lines showed cytotoxic responses to LeTx.
Cytotoxicity of LeTx was mimicked by the specific mitogen-activated protein/extracellular signal–regulated kinase
kinase 1/2 (MEK1/2) inhibitor U0126, indicating that LeTx-induced cell death is mediated through the MEK1/2–
extracellular signal–regulated kinase (ERK1/2) branch of the MAPK pathway. The four LeTx-resistant cell lines were
sensitive to the phosphatidylinositol 3-kinase inhibitor LY294002. Co-treatment of AML cells with both LeTx and
LY294002 did not lead to increased sensitivity, showing a lack of additive/synergistic effects when both pathways
are inhibited. Flow cytometry analysis of MAPK pathway activation revealed the presence of phospho-ERK1/2 only
in LeTx-sensitive cells. Staining for Annexin V/propidium iodide and active caspases showed an increase in double-
positive cells and the absence of caspase activation following treatment, indicating that LeTx-induced cell death is
caspase-independent and nonapoptotic. We have shown that a majority of AML cell lines are sensitive to the
LF-mediated inhibition of the MAPK pathway. Furthermore, we have demonstrated that LeTx-induced cytotoxicity in
AML cells is nonapoptotic and dependent on phospho-ERK1/2 levels.
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Introduction
Acute myeloid leukemia (AML) is one of the most common leukemias
in adults with an estimated 13,780 newly diagnosed cases and an esti-
mated 10,200 deaths in the United States in 2012 [1]. Though a high
proportion of AML patients enter complete remission following com-
bination induction and consolidation chemotherapy, most patients
eventually relapse because of persistence of chemotherapy-resistant
blasts in the bone marrow [2]. Hence, alternative approaches employ-
ing novel, more selective mechanisms for targeting AML blasts are
being sought. One such approach consists of targeting the mitogen-
activated protein kinase (MAPK) pathway in AML cells using a re-
combinant anthrax lethal toxin (LeTx) [3–5].
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TheMAPK pathway is a highly conserved signaling pathway whose
activation leads to cell proliferation and survival [5,6]. Mutations
leading to the constitutive activation of the Ras–Raf–mitogen-
activated protein/extracellular signal–regulated kinase kinase 1/2
(MEK1/2)–extracellular signal–regulated kinase (ERK1/2) pathway
are a hallmark of several tumors such as melanoma and are found
in a variety of cancers, including AML, thus constituting an attractive
target for novel AML therapies [7–10].
LeTx is a binary toxin produced by the gram positive bacterium
Bacillus anthracis and consists of two separate proteins: the cell bind-
ing and internalization moiety protective antigen (PrAg) and the
catalytic moiety lethal factor (LF) [11,12]. PrAg binds to cells
through its ubiquitously expressed cell surface receptors tumor endo-
thelial marker-8 and capillary morphogenesis gene-2 and is sub-
sequently cleaved by cell surface furin-like proteases leading to the
release of a 20-kDa fragment and the generation of an active 63-kDa
fragment (PrAg63) [5,13]. The latter then forms oligomers, binds
three to four molecules of LF, and undergoes endocytosis [14]. On
acidification of the endosome, PrAg63 oligomers undergo a conforma-
tional change leading to pore formation and allowing LF to translocate
into the cytosol [15]. LF is a zinc metalloprotease that cleaves and
inactivates MEKs, leading to the inhibition of the MAPK pathway
and subsequent growth inhibition and cell death [16–18]. We have
previously shown that cytotoxicity of LeTx to human melanoma cell
lines carrying the V600E BRAF mutation is dependent on the activa-
tion status of the MAPK pathway, particularly MEK1/2, allowing the
use of this toxin for the selective targeting of tumors with constitutive
MAPK activation [4,5,9,10,18].
We and others have previously demonstrated the potency and
selectivity of LeTx to melanoma cell lines in vitro and in an in vivo
melanoma model [4,5]. However, unlike melanoma, in which the
importance of N-Ras and BRAF mutations (found in up to 95% of
cases) is well established, the importance of MAPK pathway muta-
tions in AML has been poorly investigated [19]. Moreover, very
few attempts have been made to target the MAPK pathway in
AML, with the exception of targeting the receptor tyrosine kinase
fms-like tyrosine kinase 3 in AML cells carrying fms-like tyrosine
kinase 3 mutations [20,21]. Hence, a deeper investigation of the
MAPK pathway in human AML cell lines along with the possibility
of selectively targeting AML through the inhibition of the MAPK
pathway are warranted.
In this study, we attempt to target the MAPK pathway in AML
cell lines using a recombinant LeTx and to characterize the response
of AML cells to the LeTx-mediated inhibition of the MAPK pathway.
Materials and Methods
Expression and Purification of LeTx
Recombinant LeTx proteins PrAg and LF, as well as FP59 (fusion
of the PrAg binding domain of LF and the catalytic domain of
Pseudomonas aeruginosa exotoxin A), were expressed and purified as
described previously [22,23]. LY294002 was purchased from Cell
Signaling Technology (Danvers, MA).
Cells and Cell Lines
Human AML cell lines HL60, U937, ML1, ML2, Mono-Mac-1,
Mono-Mac-6, KG-1, SigM5, TF1-vRaf, TF1-vSrc, and TF1-HaRas
were grown as described previously [24].
Proliferation Inhibition Assay (Cytotoxicity)
Sensitivity of AML cell lines to LeTx was determined using a
proliferation inhibition assay as described previously [5]. We have also
used a recombinant protein, termed FP59, consisting of the PrAg
binding domain of LF fused to the catalytic domain of P. aeruginosa
exotoxin A. Binding of FP59 to PrAg and its translocation into the
cytosol are identical to LF; however, it does not target the MAPK
pathway but rather ADP-ribosylates elongation factor 2 leading to
inhibition of protein synthesis and cell death. PrAg/FP59 was used
as a control for catalytic domain entry into the cytosol of AML cells.
Briefly, aliquots of 104 cells/well, in 100 μl of cell culture medium,
containing a fixed concentration of 10−9 M LF or FP59, were plated
onto a flat-bottom 96-well plate (Corning Inc, Corning, NY). Then,
50 μl of PrAg in media were added to each well to yield concentrations
ranging from 10−8 to 10−13 M. When LY294002 or U0126 were
used, they were added as described above for PrAg but in concentra-
tions ranging from 10−4 to 10−9 M. Following a 48-hour incubation
at 37°C/5% CO2, 50 μl of XTT cell proliferation reagent (Roche,
Basel, Switzerland) was added to each well and the plates incubated
for another 4 hours. Absorbance was then read at 450 nm using a
microplate reader (Thermo Fisher Scientific, Waltham, MA). Nominal
absorbance and percent maximal absorbance were plotted against the
log of concentration, and a nonlinear regression with a variable slope
sigmoidal dose-response curve was generated along with inhibitory
concentration 50 (IC50) using GraphPad Prism 5 software (GraphPad
Software, San Diego, CA). All assays were performed at least twice
with an interassay range of 30% or less for IC50.
Cell Cycle Analysis
The impact of LeTx treatment on the cell cycle of AML cells was
determined using propidium iodide (PI) staining on flow cytometry.
Briefly, cells incubated with three different concentrations of LeTx
(10,000, 300, and 4.5 pM) or media alone in flat-bottom 96-well
plates (Corning Inc) for 24 and 48 hours at 37°C/5% CO2 were
harvested and fixed in 70% ethanol for a minimum of 24 hours,
at −20°C. Cells were then incubated in 500 μl of PI staining solution
(50 μg/ml) for 40 minutes at 37°C. Samples were then read on a C6
flow cytometer (BD Accuri, Ann Arbor, MI) and total cell DNA
content was measured on FL2-A. Percent of cells in G0/G1, S, and
G2/M phases was determined in control cells and in cells treated with
the three different concentrations of LeTx (10,000, 300, and 4.5 pM)
following gating for the cell population on width versus forward scatter.
Inhibition Assays
AML cells were incubated with either the small molecular weight
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 (Cell Signal-
ing Technology) alone and in combination with LeTx or with the
small molecular weight MEK1/2 inhibitor U0126 (Cell Signaling
Technology). Briefly, 104 cells/well were plated onto 100 μl of medium
in a flat-bottom, 96-well plate. Then, 100 μl of either medium (control
cells) or medium containing LeTx (10−8 M PrAg/10−9 M LF),
LY294002 (20 and 50 μM), U0126 (20 and 50 μM), or a combination
of the above were added. Cells were then incubated for 48 hours at
37°C/5% CO2 followed by the addition of 50 μl of XTT cell pro-
liferation reagent (Roche). Cells were incubated for another 4 hours
and absorbance was read at 450 nm using a 96-well plate reader
(Thermo Fisher Scientific). Data were analyzed using GraphPad
Prism 5 software (GraphPad Software). The absorbance and the
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percent absorbance of controls were compared between the different
treatment groups.
Intracellular Staining and Flow Cytometry Analysis
Activation of the MEK1/2-ERK1/2 pathway in AML cell lines
[untreated and following a 10-hour incubation with LeTx (10−8 M
PrAg/10−9 M LF)] was assessed by determining the presence or
absence of phospho-ERK1/2 using flow cytometry as described pre-
viously [25]. Approximately 3 × 106 cells were fixed in 70% ethanol
for 15 minutes. Cells were then incubated with a 1/100 dilution of
anti–phospho-ERK1/2 (Ser 217/221) rabbit monoclonal antibodies
(Cell Signaling Technology) in antibody binding buffer containing
0.05% Triton X-100, for 1 hour at 37°C, followed by a 30-minute
incubation with a 1/100 dilution of a fluorescein isothiocyanate
(FITC)–conjugated mouse anti-rabbit polyclonal antibody (Santa
Cruz Biotechnology, Santa Cruz, CA). Fixed cells stained only with
FITC-conjugated mouse anti-rabbit polyclonal antibody were used
as isotypic control. Samples were then analyzed using a C6 flow
cytometer (BD Accuri). The presence of phospho-ERK1/2 was ana-
lyzed and compared with that of the isotopic control. Positivity for
the presence of phospho-ERK1/2 was determined using the ratio of
fluorescence intensity (RFI) between the mean fluorescence intensity
of the stained cells and the mean fluorescence intensity of the isotypic
control. RFI ≥ 2 was considered positive.
Analysis of Cell Cytotoxicity
Determination of apoptotic versus nonapoptotic cell death was
carried out using an Annexin V–FITC and PI-labeled apoptosis/
necrosis detection kit (Abcam, Cambridge, MA) and an FITC-
conjugated active caspase inhibitor (ApoStat Apoptosis Detection
Kit; R&D Systems, Abingdon, England) on flow cytometry. Briefly,
104 cells/well were plated onto 100 μl of media in a flat-bottom,
96-well plate and were incubated with either 100 μl of medium alone
(control cells) or medium containing three different concentrations of
LeTx (as described above under cell cycle analysis) for 24 and 48 hours
at 37°C/5% CO2. Cells were then harvested and incubated with an
FITC-conjugated annexin V antibody (2.5 mg/ml and PI (5 mg/ml)
in antibody binding buffer for 45 minutes at 37°C or incubated with
0.5 μg/ml apostat for 30 minutes and then harvested. Cells were then
read using a C6 flow cytometer. Annexin V/PI data were analyzed on
FL1-H versus FL2-H scatter plot and active caspases were detected on
FL1-H. Unstained cells were used as negative control. Cells had to
show positive annexin V staining, negative PI staining, and positive
active caspase staining to be considered apoptotic, whereas cells positive
for both annexin V and PI staining and negative for active caspase
staining were considered nonapoptotic.
Results
Cytotoxicity of LeTx
We tested the cytotoxicity of LeTx on a panel of 11 human AML cell
lines using an XTT proliferation inhibition assay. Seven of 11 AML cell
lines (64%) were sensitive to the LF-mediated inhibition of the
MAPK pathway with IC50 = 13 to 94 pM and percent cell kill at highest
concentration >75%. The remaining four cell lines were not sensitive to
the LF-mediated inhibition of the MAPK pathway (IC50 > 10,000 pM
and percent cell kill at highest concentration ≤ 40%) (Table 1 and
Figure 1E ). To demonstrate that resistance to LeTx was due to resis-
tance to the LF-mediated inhibition of the MAPK pathway and not
to the inability of LF to translocate into the cytosol of targeted cells,
we tested the cytotoxicity of a combination of PrAg and FP59 to
AML cell lines. FP59 is a fusion of the PrAg binding domain of LF
and the catalytic domain of P. aeruginosa exotoxin A. Binding to PrAg
and translocation of FP59 into the cytosol are identical to those of LF;
however, FP59 does not target the MAPK pathway but rather ADP-
ribosylates elongation factor 2 leading to the inhibition of protein syn-
thesis and subsequent cell death. The combination of PrAg and FP59,
therefore, induces MAPK-independent cytotoxicity to all cells that
express the anthrax toxin receptors. PrAg/FP59 was cytotoxic to all
the AML cell lines tested with IC50 = 0.7 to 18 pM and percent cell
death >90%, indicating that differential sensitivity of AML cells to LeTx
is independent of the ability of LF to translocate into the cytosol (Table 1
and Figure 1, A–D ) and dependent on the addiction of cells to the
MAPK pathway. In addition, intracellular staining and flow cytometry
analysis of phospho-ERK1/2 in sensitive cell lines before and after a
10-hour incubation with LeTx revealed the absence of phospho-
ERK1/2 in cells treated with LeTx, compared to nontreated cells,
thus indicating that cytotoxicity of LeTx to AML cells is mediated
through the proteolytic cleavage of MEKs by LF and subsequent
inhibition of the MAPK pathway as evidenced by the absence on
phospho-ERK1/2 in LeTx-treated cells (data not shown). Moreover,
because LeTx inhibits all branches of the MAPK pathway, it is pos-
sible that cytotoxicity of LeTx to AML cell lines is due to the simul-
taneous inhibition of all three branches of the MAPK pathway and
not only the MEK1/2-ERK1/2 branch. Therefore, to determine the
contribution of the MEK1/2-ERK1/2 branch to the cytotoxicity of
LeTx, we tested the sensitivity of our panel of AML cell lines to
U0126, the specific MEK1/2 inhibitor. Cytotoxicity of U0126 mim-
icked that of LeTx with the same pattern seen with both LeTx and
U0126 across the panel of AML cell lines (Table 1 and Figure 1F ).
The four cell lines that were resistant to LeTx-induced cytotoxicity
were also resistant to U0126 (IC50 > 1000 μM and percent cell kill
at the highest concentration ≤ 35%), thus confirming that these cell
lines do not rely on the MAPK pathway for survival and are resistant to
both the specific inhibition of MEK1/2 and the inhibition of the entire
MAPK pathway. The seven AML cell lines that were sensitive to LeTx-
induced cytotoxicity were also sensitive to the specific MEK1/2 inhib-
itor U0126 (IC50 = 1.3–2.7 μM and percent cell kill at the highest
concentration >60%), thus indicating that cytotoxicity of LeTx is
mediated through the inhibition of the MEK1/2-ERK1/2 branch of
the MAPK pathway.
Table 1. Sensitivity of Human AML Cell Lines to LeTx (PrAg/LF), U0126, and the Protein
Synthesis Inhibitor PrAg/FP59.
Cell Line LeTx (PrAg/LF) (IC50; pM) PrAg/FP59 (IC50; pM) U0126 (IC50; μM)
HL60 13.0 0.7 2.6
TF1-VSrc 15.0 3.0 2.0
TF1-VRaf 16.0 4.0 1.3
Mono-Mac-6 39.0 13.0 2.1
SigM5 40.0 17.0 1.9
ML-2 81.0 7.0 1.5
TF1-HaRas 94.0 0.4 2.7
ML-1 >10,000 6.0 >1,000
U937 >10,000 1.0 >1,000
KG-1 >10,000 1.0 >1,000
Mono-Mac-1 >10,000 2.0 >1,000
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Cell Cycle Effect of LeTx
To determine whether, in addition to its cytotoxicity, LeTx
induces cell cycle arrest in AML cells, we determined the cell cycle
status of our panel of AML cell lines following 24- and 48-hour
incubation with three different concentrations of the LeTx. One of
the four AML cell lines that were not sensitive to the cytotoxicity of
LeTx (ML1) showed dose-dependent cell cycle arrest at 24 hours
(data not shown) and 48 hours following treatment with LeTx,
whereas the other three (U937, Mono-Mac-1, and KG-1) did not
show any effect of LeTx treatment on cell cycle (Figure 2, A and
B ). The fraction of cells in the G0/G1 phase of ML1 increased from
approximately 34% of the total cell population in control cells to
approximately 60% of the total cell population following incubation
with 10,000 pM of LeTx for 48 hours. This was associated with a
corresponding decrease in the percentage of cells in the G2/M phase
from approximately 19% of the cell population in control cells to
approximately 8% of the cell population in treated cells (Figure 2A ).
Furthermore, cell cycle arrest was observed in four of the seven cell
lines that showed a cytotoxic response to the LF-mediated inhibition
of the MAPK pathway (ML2, HL60, TF1-HaRas, and TF1-vSrc) at
24 hours (data not shown) and 48 hours following treatment with
LeTx. A dose-dependent increase in the percentage of surviving cells
in the G0/G1 phase was observed (42%, 58%, 41%, and 40% in
control cells versus 54%, 73%, 67%, and 54% in treated cells) at
48 hours, in ML2 (Figure 2C ), HL60, TF1-HaRas, and TF1-vSrc
cells, respectively. This was associated with a corresponding decrease
in the percentage of cells in the G2/M phase, by approximately 10%,
in treated versus control cells in all four cell lines. The remaining
three LeTx-sensitive cell lines [TF1-vRaf (Figure 2D), SigM5, and
Mono-Mac-6] showed complete cell death with more than 90% of
cells in the pre-G0/G1 peak and no difference in the percentage of
cells in the G0/G1 phase between control cells and surviving cells
at the highest concentration of LeTx at both 24-hour incubation
(data not shown) and 48-hour incubation. This indicates that, in
addition to significant cytotoxicity to the majority of AML cell lines,
LeTx induces cell cycle arrest in a subset of AML cells (approximately
45%) irrespective of their cytotoxic response to the LF-mediated
inhibition of the MAPK pathway.
Inhibition of PI3K
To determine whether AML cell lines resistant to the LF-mediated
inhibition of the MAPK pathway are susceptible to the inhibition of
the PI3K/Akt pathway, we tested the sensitivity of the LeTx-resistant
cell lines (ML1, Mono-Mac-1, U937, and KG-1) to the small molec-
ular weight PI3K inhibitor LY294002. Incubation with LY294002
at 20 and 50 μM for 48 hours induced significant cytotoxicity in
all four cell lines with cell viability decreasing by approximately
Figure 1. Nonlinear regression curves of LeTx (PrAg/LF) (square) and PrAg/FP59 (triangle) on human AML cell lines. HL60 (A) and TF1-vRaf
(B) cell lines are sensitive to both LeTx and PrAg/FP59. Mono-Mac-1 (C) and U937 (D) are only sensitive to PrAg/FP59 but not to PrAg/LF,
indicating resistance to the LF-mediated inhibition of the MAPK pathway. (E) Compilation of LeTx nonlinear regression curves on all
AML cell lines tested. (F) Nonlinear regression curves of the specific MEK1/2 inhibitor U0126 on TF1-vRaf (square), HL60 (triangle),
Mono-Mac-1 (inverted triangle), and U937 (diamond) cell lines. The LeTx-sensitive cell lines TF1-vRaf and HL60 are sensitive to U0126,
whereas the LeTx-resistant cell lines Mono-Mac-1 and U937 are resistant to U0126.
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40% to 50% at the 20 μM concentration and 60% to 80% at the
50 μM concentration compared to untreated cells (P < .05; Figure 3A).
Co-incubation of these cells with both LeTx (10 nM) and LY294002
(20 and 50 μM) led to only a slight decrease in cell viability, approx-
imately 10%, compared to LY294002 alone. Although the decreases in
cell viability observed following co-incubation with both LeTx and
LY294002 were statistically significant for the U937 cell line at the
20 μM concentration, the ML1 cell line at the 50 μM concentration,
and the Mono-Mac-1 and KG-1 cell lines at both the 20 and 50 μM
concentrations (P < .05), compared to LY294002 alone, they were not
considered functionally significant because co-incubation only ac-
counted for an additional decrease in cell viability of no more than
10% compared to LY294002 alone (Figure 3A). Moreover, cytotoxi-
city of the combination of LY294002 and LeTx was similar to the
cytotoxicity of either LeTx alone or LY294002 alone as evidenced by
similar nonlinear regression curves and similar IC50 values, at 48 hours,
in a proliferation inhibition assay (Figure 3, B–D). Hence, cell lines
that are not sensitive to LeTx are sensitive to the inhibition of the
PI3K/Akt pathway with the simultaneous inhibition of both path-
ways not resulting in increased cell cytotoxicity. This shows the
existence of two distinct populations of AML cell lines sensitive to
the inhibition of either the MAPK pathway or the PI3K/Akt pathway
with no additive or synergistic effect observed when both pathways are
inhibited simultaneously.
Analysis of MAPK Activation
We examined the activation level of theMAPK pathway in AML cell
lines by determining the phosphorylation status of phospho-ERK1/2,
using single-cell intracellular staining on flow cytometry. A represen-
tative sample of four AML cell lines was tested and the presence or
absence of phospho-ERK1/2 was linked to the cell response to the
LF-mediated inhibition of the MAPK pathway. Both of the cell lines
that showed a cytotoxic response to the LF-mediated inhibition of the
MAPK pathway (ML-2 andTF1-vRaf) had an activeMEK1/2-ERK1/2
pathway as evidenced by the presence of phospho-ERK1/2 (RFI =
2.14 and 2.32 for ML-2 and TF1-vRaf, respectively, compared to iso-
type control; Figure 4, A and B ). However, the two cell lines that did
not show a cytotoxic response to the LF-mediated inhibition of the
MAPK pathway (U937 and ML-1) were not positive for the presence
of phospho-ERK1/2, hence had an inactiveMEK1/2-ERK1/2 pathway
(RFI = 1.41 and 1.51 for U937 andML-1, respectively, compared to iso-
type control; Figure 4, C and D). This indicates that phospho-ERK1/2
levels may serve as a useful marker for the sensitivity of AML cells to
the inhibition of the MAPK pathway.
Analysis of Cell Death
To determine the mechanism of the cell death observed following
the LF-mediated inhibition of the MAPK pathway in AML cells, we
tested for caspase activation and annexin V/PI staining in our panel
Figure 2. Cell cycle analysis of AML cell lines following treatment with LeTx. Control cells are represented in the left panels, and cells
treated with 10 nM LeTx for 48 hours are represented in the right panels. Cells are gated on width versus forward scatter (R1). Cells in
G0/G1 are gated M2, those in G2/M are gated M3, and those in pre-G0/G1 (dead) are gated M4 or M5. One of the cell lines that did not
show a cytotoxic response to LeTx, ML1 (A), did show cell cycle arrest, whereas the other, U937 (B), did not. Similarly, one of the LeTx-
sensitive cell lines ML2 (C) showed cell cycle arrest in addition to cell death, whereas the other, TF1-vRaf (D), showed complete cell
death following treatment.
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of AML cell lines following treatment with three different concentra-
tions of LeTx (10,000, 300, and 4.5 pM) for 24 and 48 hours. The
four cell lines that did not show a cytotoxic response following
treatment with LeTx in the proliferation inhibition assay stained
negatively with both PI and Annexin V, confirming the absence of
cell death following LF-mediated inhibition of the MAPK pathway
in these cell lines. However, in all seven LeTx-sensitive cell lines
(TF1-vRaf, TF1-vSrc, TF1-HaRas, HL60, SigM5, Mono-Mac-6,
and ML-2), an increase in the percentage of cells stained with both
annexin V and PI was observed, at both 24 and 48 hours, in cells
treated at the highest concentration of LeTx (10 nM) compared to
controls, indicating either necrotic or late-stage apoptotic cell death
(Figure 5). However, staining for active caspases revealed a total
absence of caspase activation in all AML cell lines tested, following
treatment with LeTx for 24 and 48 hours (Figure 5). The absence of
caspase activation, in addition to the loss of membrane integrity as
evidenced by positive PI staining, indicates that LeTx-induced cyto-
toxicity in AML cells is mediated through caspase-independent, non-
apoptotic mechanisms.
Discussion
In this study, we have shown that LeTx is highly cytotoxic to a
majority of human AML cell lines through the LF-mediated inhibi-
tion of the MAPK pathway. Limited information exists regarding the
importance of the MAPK pathway in AML cells and the potential
targeting of AML through the inhibition of the MAPK pathway
has not been sufficiently investigated so far [19–21]. We have dem-
onstrated that differential sensitivity of AML cell lines to LeTx was
not due to the inability of the LF moiety to translocate into the
cytosol but rather to the differential sensitivity of AML cell lines
to the LF-mediated inhibition of the MAPK pathway. When we
replaced the catalytic domain of LF with the catalytic domain of
P. aeruginosa exotoxin A, which inhibits protein synthesis rather than
Figure 4. Single-cell intracellular staining of phospho-ERK1/2 in
four AML cell lines using flow cytometry. TF1-vRaf (A) and ML-2
(B) cells, which showed a cytotoxic response to the LF-mediated
inhibition of the MAPK pathway, were positive for the presence of
phospho-ERK1/2 as evidenced by an RFI > 2 between cells
stained for phospho-ERK1/2 (gray) and cells incubated with an iso-
type control (black). Cells are gated on width versus forward scat-
ter (R2 and R3). ML-1 (C) and U937 (D) cells, which were resistant
to the cytotoxicity of LeTx, were negative for phospho-ERK1/2 with
RFI < 1.5.
Figure 3. Sensitivity of LeTx-resistant AML cell lines to LY294002 alone and in combination with LeTx. (A) LeTx-resistant cell lines
incubated with LY294002 at 20 and 50 μM for 48 hours were sensitive to both concentrations of LY294002, whereas co-incubation
with LeTx (10 nM) did not lead to any significant increase in cell sensitivity. Nonlinear regression curves of U937 (B), Mono-Mac-1
(C), and TF1-vSrc (D) cells incubated with LeTx (square), LY294002 (triangle), or a combination of both (inverted triangle). The combi-
nation of LeTx and LY294002 did not lead to increased cytotoxicity compared to either LeTx or LY294002 alone.
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the MAPK pathway, differential sensitivity was lost and all AML cell
lines tested were sensitive to the combination of PrAg and FP59,
demonstrating that differential sensitivity of AML cells to LeTx
was due to the differential response of AML cell lines to the LF-
mediated inhibition of the MAPK pathway. In addition, we have
shown that the pattern of cytotoxicity of LeTx on our panel of
AML cell lines was mimicked by the specific, small molecular weight
MEK1/2 inhibitor U0126, indicating that cytotoxicity of LeTx is
mainly mediated through the inhibition of the MEK1/2-ERK1/2
branch of the MAPK pathway. Moreover, we have shown that incu-
bation of AML cells with LeTx leads to a marked inhibition of the
MEK1/2-ERK1/2 branch of the MAPK pathway as evidenced by the
absence of phosphorylated ERK1/2 in cells incubated with LeTx for
10 hours compared to nontreated cells.
The four AML cell lines that proved to be resistant to the inhibi-
tion of the MAPK pathway by LeTx were sensitive to the inhibition
of the PI3K/Akt pathway by LY294002, a small molecular weight
PI3K inhibitor. Interestingly, co-incubating AML cell lines with
both LeTx and LY294002 did not show any significant increase in
cytotoxicity compared to LY294002 alone. Therefore, the panel of
AML cell lines tested consisted of two distinct populations, one
sensitive to the inhibition of the MAPK pathway and the other sen-
sitive to the inhibition of the PI3/Akt pathway with the simultaneous
inhibition of both pathways not leading to any additive or synergistic
effects. These findings are surprising because the inhibition of both
the MEK1/2-ERK1/2 pathway and the PI3K/Akt pathway has been
shown to have additive or synergistic effects in a number of tumor
types, including hepatocellular carcinoma, colorectal cancer, pancre-
atic adenocarcinoma, and melanoma [26–29]. Moreover, it has been
shown that resistance to MEK inhibitors is mediated through the
activation of the PI3k/Akt pathway in a number of tumors [30].
Inhibition of both the MEK1/2-ERK1/2 pathway and the PI3K/
Akt pathway in AML cells has not been investigated to date. Our
results demonstrate that AML cells are sensitive to the inhibition
of either the MEK1/2-ERK1/2 pathway or the PI3K/Akt pathway
with no additive or synergistic effect for the simultaneous inhibition
of both pathways.
In addition to its cytotoxic effect on a majority of AML cell lines,
we have shown that LeTx also induces cell cycle arrest in a large subset
of cell lines, independently of their sensitivity to the cytotoxic effects
of the LF-mediated inhibition of the MAPK pathway. One of the
four cell lines that did not show a cytotoxic response to LeTx, in
addition to four of the seven cell lines that did show a cytotoxic
response, had an increase in the fraction of cells in the G0/G1 phase
along with a decrease in the fraction of cells in the G2/M and S phases
in surviving cells at the highest concentration compared to controls.
We then determined the activity of the Ras-Raf-MEK1/2-ERK1/2
pathway in AML cell lines by assessing phospho-ERK1/2 levels using
single-cell intracellular staining and comparing it to the cytotoxic
response of these cells to the LF-mediated inhibition of the MAPK
pathway. Cell lines in which the LF-mediated inhibition of the
MAPK pathway induced cytotoxicity were positive for phospho-
ERK1/2 indicating an active Ras-Raf-MEK1/2-ERK1/2 pathway,
whereas cell lines in which the inhibition of this pathway did not
induce cytotoxicity were negative for phospho-ERK1/2. This indi-
cates that sensitivity of AML cells to the LF-mediated inhibition of
the MAPK pathway is determined by the activity of the MAPK path-
way and that phospho-ERK1/2 levels may be used as a marker to
predict sensitivity of AML cells to the inhibition of the MAPK path-
way. Predicting a cell response to the inhibition of a signaling path-
way, such as the MAPK pathway, may be more complicated than a
simple determination of the activity of the pathway; however, in the
absence of alternatives, this remains the only available means of
assessing the importance of a particular pathway to the survival of cells.
Analysis of the mechanism of cell death in AML cell lines follow-
ing LF-mediated inhibition of the MAPK pathway revealed that
LeTx induces caspase-independent, nonapoptotic cell death in
AML cells. Cells treated with LeTx for 24 hours were positive for
both Annexin V and PI while being negative for the presence of
active caspases. LeTx has been shown to induce caspase-dependent,
apoptotic cell death in a number of tumor types, including mela-
noma [4]. However, LeTx-mediated inhibition of the MAPK path-
way has not been investigated in AML cells and the type of cell death
induced by the LF-mediated inhibition of this pathway may be
dependent on the tumor type. Furthermore, though some studies
have shown that Ras inhibitors and MEK inhibitors do induce
apoptosis in AML cell lines, the nonapoptotic cell death induced
by LeTx in AML cells is not surprising knowing the different
mechanism of action of LeTx that catalytically cleaves all MEKs
leading to the complete inhibition of all branches of the MAPK
pathway [31–33].
In this study, we have shown that a majority of AML cell lines are
sensitive to the LF-mediated inhibition of the MAPK pathway, hence
confirming the potential for selectively targeting this pathway in
AML. Furthermore, we have demonstrated that LeTx-induced cyto-
toxicity in AML cells, following inhibition of the MAPK pathway, is
nonapoptotic and is dependent on phospho-ERK1/2 levels in tar-
geted cells.
Figure 5. Analysis of the mechanism of LeTx-mediated cytotoxi-
city in TF1-vRaf cells using annexin V/PI (A) and active caspase
staining (B). TF1-vRaf cells incubated with 10 nM LeTx for 24 hours
(right panel) stained positively with both annexin V (FL1-H) and PI
(FL2-H). Incubation of LeTx-treated TF1-vRaf cells with a cell per-
meable, FITC-conjugated active caspase inhibitor revealed the ab-
sence of active caspases following incubation with LeTx (gray).
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